ESR1 and breast neoplasm: In another cohort of 18 ER+ breast tumors treated with an aromatase inhibitor (cohort of Miller et al.22), PRR11 mRNA was not downregulated in post-treatment compared to pre-treatment tumors (Supplementary Fig. 1c), implying PRR11 is not regulated by ligand-induced ER in vivo.